Human Annexin Ⅰ(ANX-Ⅰ) ELISA Kit CSB-E12155h CUSABIO
$50.00
In stock
SKU
CSB-E12155h
Product Details
| Target Name | annexin A1 |
| Uniprot No. | P04083 |
| Species | Homo sapiens (Human) |
| Storage | Store at 2-8°C. Please refer to protocol. |
| Sensitivity | 0.078 ng/mL |
| Troubleshooting and FAQs | ELISA kit FAQs |
| Lead Time | 3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx. |
| Associated names | Annexin 1 ELISA Kit; Annexin A1 ELISA Kit; Annexin I (lipocortin I) ELISA Kit; Annexin I ELISA Kit; Annexin-1 ELISA Kit; AnnexinA1 ELISA Kit; AnnexinI ELISA Kit; ANX 1 ELISA Kit; ANX A1 ELISA Kit; ANX1 ELISA Kit; ANXA 1 ELISA Kit; ANXA1 ELISA Kit; ANXA1 protein ELISA Kit; ANXA1_HUMAN ELISA Kit; Calpactin 2 ELISA Kit; Calpactin II ELISA Kit; Calpactin-2 ELISA Kit; CalpactinII ELISA Kit; Chromobindin 9 ELISA Kit; Chromobindin-9 ELISA Kit; Chromobindin9 ELISA Kit; HGNC:533 ELISA Kit; Lipocortin 1 ELISA Kit; Lipocortin I ELISA Kit; Lipocortin1 ELISA Kit; LipocortinI ELISA Kit; LPC 1 ELISA Kit; LPC1 ELISA Kit; p35 ELISA Kit; Phospholipase A2 inhibitory protein ELISA Kit |
| Abbreviation | ANXA1 |
| Sample Types | serum, plasma, tissue homogenates |
| Detection Range | 0.312 ng/mL-20 ng/mL |
| Assay Time | 1-5h |
| Sample Loading Volume | 50-100ul |
| Detection Wavelength | 450 nm |
| Research Area | Signal Transduction |
| Assay Principle | quantitative |
| Measurement | Sandwich |
| Precision | headers: Intra-assay Precision (Precision within an assay): CV%<8%; rows: Intra-assay Precision (Precision within an assay): CV%<8%: Intra-assay Precision (Precision within an assay): CV%<8%; 1: Three samples of known concentration were tested twenty times on one plate to assess.; Intra-assay Precision (Precision within an assay): CV%<8%: Inter-assay Precision (Precision between assays): CV%<10%; 1: Three samples of known concentration were tested in twenty assays to assess.; |
| Linearity | headers: To assess the linearity of the assay, samples were spiked with high concentrations of human ANX-Ⅰ in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.; rows: To assess the linearity of the assay, samples were spiked with high concentrations of human ANX-Ⅰ in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.: To assess the linearity of the assay, samples were spiked with high concentrations of human ANX-Ⅰ in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.; 2: Sample; 3: Serum(n=4); 1: 1:1; 2: Average %; 3: 85; 1: Range %; 2: 81-93; 1: 1:2; 2: Average %; 3: 95; 1: Range %; 2: 90-100; 1: 1:4; 2: Average %; 3: 98; 1: Range %; 2: 91-106; 1: 1:8; 2: Average %; 3: 92; 1: Range %; 2: 80-98 |
| Recovery | headers: The recovery of human ANX-Ⅰ spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.; rows: The recovery of human ANX-Ⅰ spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.: The recovery of human ANX-Ⅰ spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.; 1: Sample Type; 2: Average % Recovery; 3: Range; 1: Serum (n=5); 2: 92; 3: 80-110; 1: EDTA plasma (n=4); 2: 96; 3: 91-101; ; |
| Typical Data | headers: These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.; rows: These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.: These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.; 1: ng/ml OD1 OD2 Average Corrected 20 1.958 1.872 1.915 1.772 10 1.794 1.696 1.745 1.602 5 1.405 1.384 1.395 1.252 2.5 0.887 0.839 0.863 0.720 1.25 0.534 0.524 0.529 0.386 0.625 0.342 0.319 0.331 0.188 0.312 0.236 0.219 0.228 0.085 0 0.149 0.137 0.143; 2: ng/ml; 3: OD1; 4: OD2; 5: Average; 6: Corrected; 8: 20; 9: 1.958; 10: 1.872; 11: 1.915; 12: 1.772; 14: 10; 15: 1.794; 16: 1.696; 17: 1.745; 18: 1.602; 20: 5; 21: 1.405; 22: 1.384; 23: 1.395; 24: 1.252; 26: 2.5; 27: 0.887; 28: 0.839; 29: 0.863; 30: 0.720; 32: 1.25; 33: 0.534; 34: 0.524; 35: 0.529; 36: 0.386; 38: 0.625; 39: 0.342; 40: 0.319; 41: 0.331; 42: 0.188; 44: 0.312; 45: 0.236; 46: 0.219; 47: 0.228; 48: 0.085; 50: 0; 51: 0.149; 52: 0.137; 53: 0.143; 1: ng/ml; 2: OD1; 3: OD2; 4: Average; 5: Corrected; 1: 20; 2: 1.958; 3: 1.872; 4: 1.915; 5: 1.772; 1: 10; 2: 1.794; 3: 1.696; 4: 1.745; 5: 1.602; 1: 5; 2: 1.405; 3: 1.384; 4: 1.395; 5: 1.252; 1: 2.5; 2: 0.887; 3: 0.839; 4: 0.863; 5: 0.720; 1: 1.25; 2: 0.534; 3: 0.524; 4: 0.529; 5: 0.386; 1: 0.625; 2: 0.342; 3: 0.319; 4: 0.331; 5: 0.188; 1: 0.312; 2: 0.236; 3: 0.219; 4: 0.228; 5: 0.085; 1: 0; 2: 0.149; 3: 0.137; 4: 0.143 |
| Materials provided | A micro ELISA plate --- The 96-well plate has been pre-coated with an anti-human ANXA1 antibody.This dismountable microplate can be divided into 12 x 8 strip plates. Two vials lyophilized standard ---Dilute a bottle of the standard at dilution series, read the OD values, and then draw a standard curve. One vial Biotin-labeled ANXA1 antibody (100 x concentrate) (120 μl/bottle) ---Act as the detection antibody. One vial HRP-avidin (100 x concentrate) (120 μl/bottle) ---Bind to the detection antibody and react with the TMB substrate to make the solution chromogenic. One vial Biotin-antibody Diluent (15 ml/bottle) ---Dilute the Biotin-antibody. One vial HRP-avidin Diluent (15 ml/bottle) ---Dilute the HRP-avidin solution. One vial Sample Diluent (50 ml/bottle)---Dilute the sample to an appropriate concentration. One vial Wash Buffer (25 x concentrate) (20 ml/bottle) ---Wash away unbound or free substances. One vial TMB Substrate (10 ml/bottle) ---Act as the chromogenic agent. TMB interacts with HRP, eliciting the solution turns blue. One vial Stop Solution (10 ml/bottle) ---Stop the color reaction. The solution color immediately turns from blue to yellow. Four Adhesive Strips (For 96 wells) --- Cover the microplate when incubation. An instruction manual |
| Materials not provided | A microplate reader capable of measuring absorbance at 450 nm, with the correction wavelength set at 540 nm or 570 nm. An incubator can provide stable incubation conditions up to 37°C±5°C. Centrifuge Vortex Squirt bottle, manifold dispenser, or automated microplate washer Absorbent paper for blotting the microtiter plate 50-300ul multi-channel micropipette Pipette tips Single-channel micropipette with different ranges 100ml and 500ml graduated cylinders Deionized or distilled water Timer Test tubes for dilution |
| ELISA Data Analysis | ELISA Standard Curve & Curve Expert software |
| Shelf Life | 6 months |
| Description | The ELISA Kit is designed for quantitatively measuring human ANXA1 levels in samples, including serum, plasma, or tissue homogenates. It uses the sandwich enzyme immunoassay technique in combination with the enzyme-substrate chromogenic reaction to quantify the analyte in the sample. The color develops positively to the amount of ANXA1 in samples. The color intensity is measured at 450 nm via a microplate reader. ANXA1 is a calcium-dependent phospholipid-binding protein with a phospholipase A2 inhibitory activity. ANXA1 exerts multiple roles in important biological processes such as cell differentiation, proliferation, plasma membrane repair, epithelial repair, and cell apoptosis. In normal health conditions, ANXA1 plays a major protective role in the brain through the promotion of blood-brain-barrier (BBB) integrity. Several studies have indicated a role for ANXA1 in neurological diseases, including Alzheimer’s disease (AD) and stroke. Studies have also shown that ANXA1 is involved in multiple anti-inflammatory processes, including regulation of neutrophil migration, macrophage phagocytosis, and induction of changes in cell polarity of microglial cells after ischemia-like injury in vitro. |
MDSD
Reviews
Write Your Own Review